Clarity’s theranostic prostate cancer trial advances to highest dose level
Sydney, Australia 10 August 2023 Highlights Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been completed in 3 participants who received therapy with 67Cu SAR-bisPSMA at the dose level of 8GBq. No dose limiting toxicities (DLTs) have been reported in cohort 2. The Safety Review Committee…